Compass Therapeutics, Inc. CMPX 深 沪
等待开盘 07-02 09:30:00 美东时间
2.175
-0.015
-0.68%
华盛通- 最 高2.21
- 今 开2.18
- 成交量 90.52万股
- 最 低 2.13
- 昨 收 2.19
- 总市值 3.92亿
- 52周最高 6.88
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 1.61
- 委 比 10.24%
- 总股本 1.80亿
- 历史最高 6.88
- 量 比 0.48
- 振 幅 3.65%
- 历史最低 0.765
- 每 手 1
- 风险率 1.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Compass Therapeutics Adopts Second Amended and Restated Bylaws
Compass Therapeutics ( ($CMPX) ) has provided an update. On June 22, 2026, Comp...
06-23 18:50
Compass Therapeutics sets Delaware, Massachusetts federal courts as exclusive venue for Securities Act claims
Compass Therapeutics sets Delaware, Massachusetts federal courts as exclusive venue for Securities Act claims Compass Therapeutics adopted second amended and restated bylaws effective June 22, 2026. New provisions set exclusive venue in the US District Courts for Delaware or Massachusetts for Securi
06-23 18:01
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight
Compass Therapeutics ( ($CMPX) ) just unveiled an announcement. On June 10, 202...
06-12 05:24
Compass Therapeutics' CTX-8371 Dual PD-1/PD-L1 Bispecific Shows Durable Monotherapy Responses In Advanced Checkpoint-Resistant Cancers With Favorable Safety Profile
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies
05-22 05:08
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics' CTX-8371, a novel PD-1×PD-L1 bispecific antibody, showed promising clinical activity in patients with advanced malignancies resistant to prior checkpoint inhibitors. Notable deep and durable responses were observed in triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC). The drug demonstrated a favorable safety profile with no dose-limiting toxicities (DLTs) and was well tolerat...
05-21 21:00
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group May 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, Lumentum Holdings and TransDigm Group, on Wednesday. HIGHLIGHTS * Advanced Micro Devices AMD.O : Ev
05-06 15:13
Compass Therapeutics Q1 EPS $(0.10), Inline
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last
05-05 19:52
Compass Therapeutics GAAP EPS of -$0.10 in-line
Compass Therapeutics press release (CMPX): Q1 GAAP EPS of -$0.10 in-line. As of March 31, 2026, cash and marketable securities were $195 million as compared to $209 million as of December 31, 2025, a ...
05-05 19:35
William Blair updates conviction stock list
William Blair updated its 2026 conviction stock list, swapping in three new names. Additions Somnigroup International Inc. (SGI): Added to the Consumer sector by analyst Phillip Blee. The rationale is...
05-04 18:37
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
